Shield Technology
This article was originally published in The Tan Sheet
Executive Summary
Company's Chimal Technology Skin Shield and StarLee Skin Shield "do not qualify for evaluation under the ongoing OTC Drug Review," are unapproved new drugs and are misbranded, FDA says in a March 16 warning letter. Labeling indicates the topical products "are intended to form an impervious 'barrier' or 'shield' on the skin," the agency says, adding the products are promoted as comparable to gloves in preventing adverse effects and diseases caused by contact with various substances, and claim to prevent contracting viral diseases such as AIDS. The Tulsa, Okla.-based firm is scheduled to meet with FDA April 18 to discuss the letter. The firm's products are sold through distributors to the medical, food and cosmetic industries
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning